Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves OTREXUP injection for adults with RA, children with active pJIA

FDA approves OTREXUP injection for adults with RA, children with active pJIA

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

ACR journals publish guide that provides new treatments for children with systemic JIA

ACR journals publish guide that provides new treatments for children with systemic JIA

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy